Seeking ‘continuous’ run of deals, BioMarin adds Fabry, Pompe drugs via $4.8B Amicus takeout

BioMarin’s $4.8 billion purchase of Amicus represents a giant step toward the California biotech’s vision of its future, with a strategy EVP and CBO James Sabry describes as “business development as a way of life.”

Pending completion, the transaction will give BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) two marketed products for Fabry disease and Pompe disease that are likely to generate about $600 million in total 2025 revenues, as well as a Phase III program for a rare kidney disease...